Protocol: Wake Forest WF-1806
Please Note: Below is partial eligibility, for full eligibility requirements, please contact GHCI Research Department at (810) 762-8181, (810) 762-8079 and/or (810) 762-8038. Thank you!
Eligibility:
- Older adults (age ≥ 60y) with either: 1. Newly diagnosed metastatic CRC or 2. Newly recognized metastatic recurrence or CRC greater than 1 year from completion of treatment for non-metastatic CRC.
- Planning to undergo immunotherapy and/or 5/FU based chemotherapy as first line of treatment. 5-FU chemotherapy can be 5-FU alone or in combination with oxaliplatin and/or irinotecan; +/- immunmotherapy. Capecitabine is also acceptable.
- Life expectancy greater than or equal to 6 months.
- Patient eligibility is not dependent on BMI or weight. Patients with a significant (+- > 10%) body weight change in the previous 12 months are eligible for this study.
Ineligibility:
- Patients enrolled in hospice.
- Prior systemic chemotherapy for metastatic colorectal cancer (acceptable if adjuvant chemotherapy completed greater to or equal to 12 months prior disease recurrence).
- Patients may not be receiving any other investigational agents.
- No untreated brain metastases. Patients with treated brain metastases are eligible.
- Patients on or planned to undergo radiation therapy in the near future.